Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 230

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 230
---

offering with respect to the Company and all other holders of our securities, not to (a) offer, pledge, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend,
or otherwise transfer or dispose of, directly or indirectly, any shares of our capital stock or any securities convertible into or
exercisable or exchangeable for shares of our capital stock; (b) file or caused to be filed any registration statement with the
Commission relating to the offering of any shares of our capital stock or any securities convertible into or exercisable or
exchangeable for shares of our capital stock; (c) complete any offering of our debt securities, other than entering into a line of
credit with a traditional bank or (d) enter into any swap or other arrangement that transfers to another, in whole or in part, any
of the economic consequences of ownership of our capital stock, whether any such transaction described in clause (a), (b), (c) or
(d) above is to be settled by delivery of shares of our capital stock or such other securities, in cash or otherwise. We agree to
file a customary universal shelf registration statement within 30 days of the earlier of (i) the expiration of the restricted period
described above and (ii) the date of its initial eligibility to do so. Additionally, we agree that for a period of 24 months after
the offering we will not directly or indirectly offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose
of shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our capital stock in
any “at-the-market”, continuous equity or variable rate transaction, without the prior written consent of the
Representative.

Right of First Refusal

We will grant the Representative
a right of first refusal, for a period of 36 months from the closing of the offering, to act as sole investment banker, sole book-runner
and/or sole placement agent, at the Representative’s sole discretion, for each and every future public and private equity and debt
offering, including all equity linked financings, during such 36-month period, for us, or any successor to or any subsidiary of us, on
terms customary for the Representative. The Representative will have the sole right to determine whether any other broker-dealer shall
have the right to participate in any such